BHVN Biohaven Pharmaceutical Holding Co Ltd

  1. Stocks
  2. Healthcare
  3. NYSE: BHVN

Price (delayed)

$126.51

Market cap

$8.23B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$14.26

Enterprise value

$8.04B

Highlights
BHVN's revenue has soared by 67% QoQ
The company's gross profit has surged by 66% QoQ
The company's quick ratio fell by 48% YoY but it rose by 7% QoQ
Biohaven Pharmaceutical Holding's net income has decreased by 34% YoY and by 12% QoQ
The EPS has declined by 13% year-on-year and by 9% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://biohavenpharma.com/
Peers: OTIC ORIC

Key stats

What are the main financial stats of BHVN
Market
Shares outstanding
65.07M
Market cap
$8.23B
Enterprise value
$8.04B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
73.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
75.62
Earnings
Revenue
$106.3M
EBIT
-$811.65M
EBITDA
-$797.15M
Free cash flow
-$781.12M
Per share
EPS
-$14.26
Free cash flow per share
-$12.59
Book value per share
-$4.46
Revenue per share
$1.71
TBVPS
$15.23
Balance sheet
Total assets
$1B
Total liabilities
$1.22B
Debt
$270.76M
Equity
-$275.98M
Working capital
$504.91M
Liquidity
Debt to equity
-0.98
Current ratio
2.28
Quick ratio
1.83
Net debt/EBITDA
0.24
Margins
EBITDA margin
-749.9%
Gross margin
71.7%
Net margin
-807.9%
Operating margin
-686.9%
Efficiency
Return on assets
-118.6%
Return on equity
N/A
Return on invested capital
-251.7%
Return on capital employed
-133.6%
Return on sales
-763.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BHVN stock price

How has the Biohaven Pharmaceutical Holding stock price performed over time
Intraday
2.92%
1 week
0.54%
1 month
29.46%
1 year
77.86%
YTD
47.6%
QTD
30.32%

Financial performance

How have Biohaven Pharmaceutical Holding's revenue and profit performed over time
Revenue
$106.3M
Gross profit
$76.17M
Operating income
-$730.12M
Net income
-$858.83M
Gross margin
71.7%
Net margin
-807.9%
The net margin has soared by 99% year-on-year and by 33% since the previous quarter
BHVN's operating margin has surged by 99% year-on-year and by 32% since the previous quarter
BHVN's revenue has soared by 67% QoQ
The company's gross profit has surged by 66% QoQ

Growth

What is Biohaven Pharmaceutical Holding's growth rate over time

Valuation

What is Biohaven Pharmaceutical Holding stock price valuation
P/E
N/A
P/B
N/A
P/S
73.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
75.62
The EPS has declined by 13% year-on-year and by 9% since the previous quarter
Biohaven Pharmaceutical Holding's equity has increased by 29% from the previous quarter
BHVN's revenue has soared by 67% QoQ
The price to sales (P/S) is 55% less than the last 4 quarters average of 162.7

Efficiency

How efficient is Biohaven Pharmaceutical Holding business performance
The return on sales has surged by 99% year-on-year and by 35% since the previous quarter
BHVN's ROIC is up by 26% since the previous quarter
BHVN's ROA is up by 16% year-on-year and by 6% since the previous quarter

Dividends

What is BHVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BHVN.

Financial health

How did Biohaven Pharmaceutical Holding financials performed over time
The total assets is 18% smaller than the total liabilities
BHVN's total liabilities has surged by 197% year-on-year and by 20% since the previous quarter
The total assets has surged by 88% year-on-year and by 46% since the previous quarter
The debt is 198% greater than the equity
BHVN's debt to equity is down by 42% since the previous quarter
Biohaven Pharmaceutical Holding's equity has increased by 29% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.